The glucagon test in obstructive and hepatocellular jaundice

DAVID A. BERSTOCK  
F.R.C.S.  

JOHN R. WOOD  
B.S.c., M.B. B.S.  

ROGER WILLIAMS  
M.D., F.R.C.P.  

Department of Surgery and Liver Unit, King’s College Hospital and Medical School, London SE5 8RX

Summary

The plasma glucose response to an intravenous bolus of glucagon was examined in patients with obstructive jaundice, hepatocellular jaundice and in healthy volunteers. Plasma glucose levels were determined before and at 15, 30 and 45 min after glucagon. The glucose response to glucagon differed markedly in the two patient groups with significantly higher plasma glucose values in the obstructive jaundice group.

Measurement of blood glucose after intravenous glucagon provides a simple test to assist in the differential diagnosis of obstructive and hepatocellular jaundice.

Introduction

Intravenous administration of glucagon to normal man is known to increase plasma concentrations of glucose, adenosine 3’5’-cyclic monophosphate (cyclic AMP) and insulin. Glucagon acts to stimulate adenylate cyclase in liver cells resulting in glycogenolysis and gluconeogenesis (Francavilla, Jones and Starzl, 1978). Van Itallie and Bentley (1955) infused glucagon into normal subjects and cirrhotic patients in the presence and absence of subcutaneously administered adrenaline and suggested that glucagon-adrenaline induced hyperglycaemia may be of value as an index of liver function. Patients with acute viral hepatitis and healthy subjects also showed a marked difference in their plasma glucose response to intravenous glucagon (Felig et al., 1970).

Verhaegen and colleagues (1971) reported on the use of a ‘double glucagon test’, involving two intravenous doses of glucagon, in the differential diagnosis of liver cell impairment and hepatic obstruction. The present study examines the blood glucose response to a single intravenous bolus injection of glucagon in patients with confirmed hepatocellular and obstructive jaundice and also in healthy volunteers.

Patients and methods

Informed consent was obtained from all patients and volunteers. The glucagon test was performed in 39 unselected jaundiced patients and 21 healthy volunteers. Only subjects eating normally and without diabetes mellitus were studied. The diagnosis of hepatocellular jaundice (alcoholic cirrhosis, primary biliary cirrhosis, chronic active hepatitis, hepatitis B, paracetamol overdose and hepatic secondary deposits) in 21 patients and obstructive jaundice in 18 patients was confirmed in all cases by either liver biopsy or by findings at laparotomy. Five of the patients in the obstructive group had carcinoma of the pancreas and 13 had gallstones, 6 of whom had symptoms suggesting cholangitis.

All subjects were starved overnight for a minimum of 8 hr. Patients having intravenous fluids were given only saline during this period. Venous blood samples were taken for estimation of fasting plasma glucose prior to a bolus injection of glucagon (Eli Lilly, 0.025 mg/kg body weight). Further blood samples were taken 15, 30, and 45 min after glucagon injection for plasma glucose estimation.

Results

Figure 1 shows the plasma glucose response over 45 min to glucagon injection in patients with obstructive and hepatocellular jaundice and in healthy volunteers. Basal plasma glucose concentrations in obstructive jaundice (mean 5.6±0.2 s.e.mean mmol/litre) were significantly higher (P<0.005) than those in the hepatocellular (3.9±0.2 mmol/litre) or normal (4.3±0.1 mmol/litre) groups. The rise in plasma glucose after glucagon was more marked in

Correspondence to Dr John R. Wood, Department of Surgery, King’s College Hospital, Medical School, London SE5 8RX.
obstructive than in hepatocellular jaundice. The difference between the two patient groups was highly significant ($P<0.0005$) at 15 min (6.7 ± 0.3 v. 4.8 ± 0.2 mmol/litre), 30 min (7.7 ± 0.3 v. 5.2 ± 0.2) and 45 min (7.9 ± 0.4 v. 5.0 ± 0.2). The two groups were best differentiated at 45 min where only patients with obstructive jaundice (78% of the obstructive group) had plasma glucose levels greater than 7.0 mmol/litre. Mean plasma glucose concentrations in normal subjects were 6.3 ± 0.1, 6.2 ± 0.2 and 4.8 ± 0.2 mmol/litre at 15, 30 and 45 min respectively. The glucose response to glucagon in 5 patients with pancreatic carcinoma did not differ significantly from the response in the 13 patients with gallstones.

The low levels of fasting glucose found in a large proportion of the hepatocellular group have been observed previously in patients with viral hepatitis (Felig et al., 1970). The underlying mechanisms involved in the differing response of jaundiced patients to glucagon are likely to be complex resulting from differences in hepatic glycogen content, insulin and glucose metabolism and other factors affecting carbohydrate metabolism. It is of some interest that patients with longstanding obstruction showed a marked rise in blood sugar after glucagon, whilst two patients who had very mild hepatitis clinically with little or no constitutional upset, nor any marked biochemical abnormality other than a raised bilirubin, had very flat glucose response curves to glucagon. These cases serve to emphasize the possible value of the above test which when used in conjunction with other biochemical investigations may increase the accuracy of diagnosis in jaundice.

**References**


The glucagon test in obstructive and hepatocellular jaundice

David A. Berstock, John R. Wood and Roger Williams

doi: 10.1136/pgmj.58.682.485

Updated information and services can be found at:
http://pmj.bmj.com/content/58/682/485

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/